PFIZER INC.
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 1849-01-01
- Employees
- 88K
- Market Cap
- $163.3B
- Website
- http://www.pfizer.com
Study To Assess The Effect Of PF-04531083 On Heat Pain In Healthy Volunteers With Ultraviolet Light Sensitized Skin
- Conditions
- Healthy
- Interventions
- Drug: Placebo suspensionDrug: Placebo tablet
- First Posted Date
- 2010-05-21
- Last Posted Date
- 2010-09-23
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 36
- Registration Number
- NCT01127906
- Locations
- 🇧🇪
Pfizer Investigational Site, Bruxelles, Belgium
Postlicensure Observational Safety Study of 13vPnC Administered to Infants and Toddlers
- Conditions
- Pneumococcal Disease
- Interventions
- Other: No Intervention
- First Posted Date
- 2010-05-21
- Last Posted Date
- 2014-07-14
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 53902
- Registration Number
- NCT01128426
- Locations
- 🇺🇸
Northern California Kaiser Permanente, Oakland, California, United States
Study Estimating the Impact of Prevnar 13™ (13vPnC) on Invasive Pneumococcal Disease
- Conditions
- Invasive Pneumococcal Disease
- Interventions
- Other: No intervention
- First Posted Date
- 2010-05-21
- Last Posted Date
- 2018-12-04
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 1
- Registration Number
- NCT01128439
- Locations
- 🇺🇸
Kaiser Permanente Vaccine Study Center, Oakland, California, United States
A Study To Investigate The Taste Of Crizotinib Liquid In Trained Healthy Adult Volunteers
- First Posted Date
- 2010-05-19
- Last Posted Date
- 2010-07-23
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 5
- Registration Number
- NCT01125904
- Locations
- 🇺🇸
Pfizer Investigational Site, Woburn, Massachusetts, United States
Multiple Intravenous Dose Study Of PF-04360365 In Japanese Patients With Mild To Moderate Alzheimer's Disease
- Conditions
- Alzheimer's Disease
- Interventions
- Biological: PF-04360365 8.5 mg/kgDrug: Placebo
- First Posted Date
- 2010-05-18
- Last Posted Date
- 2011-08-12
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 8
- Registration Number
- NCT01125631
- Locations
- 🇯🇵
Pfizer Investigational Site, Kanazawa, Ishikawa, Japan
A Safety Study Of BMP-655/ACS As An Adjuvant Therapy For Treatment Of Rotator Cuff Tears
- Conditions
- Rotator Cuff Tear
- Interventions
- Biological: BMP-655/ACS+Standard of care or Standard of care
- First Posted Date
- 2010-05-13
- Last Posted Date
- 2013-02-22
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 23
- Registration Number
- NCT01122498
- Locations
- 🇯🇵
Pfizer Investigational Site, Nagano, Japan
Efficacy And Safety Of Sunitinib In Patients With Advanced Well-Differentiated Pancreatic Neuroendocrine Tumors
- First Posted Date
- 2010-05-12
- Last Posted Date
- 2014-06-30
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 12
- Registration Number
- NCT01121562
- Locations
- 🇯🇵
National Cancer Center Hospital, Chuo-ku, Tokyo, Japan
🇯🇵Kyushu University Hospital, Fukuoka, Japan
🇯🇵Aichi Cancer Center Central Hospital, Nagoya, Aichi, Japan
A Non-Interventional Study With Aromasin® As Adjuvant Treatment Of Invasive Early Breast Cancer
- First Posted Date
- 2010-05-12
- Last Posted Date
- 2014-01-22
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 378
- Registration Number
- NCT01121549
- Locations
- 🇷🇴
Spitalul Judeţean Brasov, Brasov, Jud. Brasov, Romania
🇷🇴Spitalul Judetean Bistrita Nasaud - Sectia Oncologie Medicala, Bistrita, Jud. Nasaud, Romania
🇷🇴Spitalulul Municipal de Urgenta Roman, Roman, Neamt, Romania
Studying An Investigational Drug Crizotinib (PF-02341066) In Non Non-Small Cell Lung Cancer Tumors That Are Positive For Anaplastic Lymphoma Kinase (ALK)
- First Posted Date
- 2010-05-12
- Last Posted Date
- 2025-01-23
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 44
- Registration Number
- NCT01121588
- Locations
- 🇺🇸
Highlands Oncology Group, Rogers, Arkansas, United States
🇺🇸Washington University School of Medicine, Saint Louis, Missouri, United States
🇺🇸Oregon Health and Science University, Portland, Oregon, United States
Study Evaluating Desvenlafaxine Succinate Sustained-Release (DVS SR) In The Treatment Of Peri- And Postmenopausal Women With Major Depressive Disorder (DVS 3364)
- Conditions
- Major Depressive Disorder
- Interventions
- Drug: placebo
- First Posted Date
- 2010-05-12
- Last Posted Date
- 2012-04-04
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 439
- Registration Number
- NCT01121484
- Locations
- 🇺🇸
Pacific Clinical Research Medical Group, Upland, California, United States
🇺🇸Midwest Clinical Research Center, Dayton, Ohio, United States
🇺🇸Carman Research, Smyrna, Georgia, United States